GHRS
GH Research Plc
NASDAQ · Healthcare · Biotechnology · IE
$18.28
+0.72%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$18.15
From 52W high−40.34%
Volume323224.00
Market cap$1.25B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$18.15
From 52W high
−40.34%
Volume
323224.00
Market cap
$1.25B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−14.5x
P/E (TTM)
—
RSI (14)
22.5
MomentumView details →
1D Return
+0.72%
YTD Return
+43.03%
SummaryUpdated Jun 1, 2026
GH Research PLC (NASDAQ:GHRS) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Dublin, Ireland. The company went public in June 2021 and focuses on developing innovative therapies for psychiatric and neurological disorders using psychedelic compounds. GH Research is at the forefront of the emerging psychedelic medicine sector, specifically developing treatments based on <b>5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT)</b>, a naturally occurring psychedelic compound. The company is currently advancing multiple drug candidates through clinical trials, with its lead program targeting treatment-resistant depression.
Similar companies
Latest newsMore news →
GH Research PLC completed GH001-HV-106, a Phase 1 clinical pharmacology trial of its proprietary aerosol delivery device in healthy volunteers, and GH001-HV-109, an IND-opening Phase 1 trial of GH001 in healthy volunteers in the United States.75d agoGH Research PLC reported financial results for the quarter ended June 30, 2026, with cash, cash equivalents and marketable securities of $362.7 million as of that date.75d ago